Project Grant R41DA050364

The National Cancer Institute (NCI) awarded a $179,403 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Nebraska Medical Center (UNMC) to develop and screen novel flupirtine analogue compounds as non-opioid analgesics for treating chemotherapy-induced neuropathic pain (CINP). The 2-year project aims to synthesize and evaluate flupirtine analogues that can effectively relieve CINP while mitigating the liver toxicity concerns associated with the parent...

The National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $818,360 Cooperative Agreement to the University of Southern California (USC) to develop new highly potent and safe Angiotensin AT2 receptor (AT2R) antagonists for the treatment of neuropathic pain. This 4-year project aims to optimize a novel lead series of AT2R antagonists that have demonstrated better potency and...

This Project Grant award from the National Institutes of Health's John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $5,000 to the University of California, San Diego to discover novel natural products that are potent blood-brain barrier (BBB) permeable inhibitors of the enzyme cathepsin L. The goal is to identify a lead drug candidate that can reduce spinal dynorphin and alleviate chronic pain without the risk of addiction, which is a...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,510,066 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation to conduct a planning study for the development of sigma 2 ligands as novel analgesics for chronic neuropathic pain. The funding will support an interdisciplinary research team to: (1) develop an in-silico library of potential sigma 2 ligand analogs, (2) synthesize and evaluate...

The National Institute on Drug Abuse (NIDA) awarded a $220,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Amalgent Therapeutics, Inc. in Greenville, NC. This grant supports the development of a novel opioid adjuvant technology that aims to enhance the pain-relieving efficacy of opioid medications while mitigating risks such as abuse potential, tolerance, and neuropathic pain. The project has two key objectives: 1) investigating the mechanism by which the...

The Cooperative Agreement award of $3,138,031 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports the clinical development of SBS-147, a first-in-class oral arylepoxamide agonist for pain management. The funding will enable Sparian Biosciences Inc., doing business as Palion Therapeutics, to advance the compound through preclinical and early clinical development stages, including Phase 1 safety studies and proof-of-concept trials. This...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $650,079 Project Grant to Northeastern University under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports the development and optimization of novel small-molecule probes targeting the alpha9 nicotinic acetylcholine receptor (α9*-nAChR) subunit, with the goal of exploring its potential for pain management. The 5-year project aims to advance...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance the development of DMX-101, a non-addictive, peripherally acting opioid analgesic, as a medication strategy to prevent opioid use disorder in patients with chronic pain. The $1,593,126 project, running from July 2025 to June 2027, will rigorously evaluate DMX-101's ability to effectively manage chronic pain without the risk of...